Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group

BMC Cancer

Volumn 12, Issue 1, 2012, Pages

  Reinacher Schick, Anke ^a,d   Schulmann, Karsten ^a   Modest, Dominik P ^b   Bruns, Nina ^a   Graeven, Ulrich ^c   Jaworska, Malgorzata ^d   Greil, Richard ^e   Porschen, Rainer ^f   Arnold, Dirk ^g   Schmiegel, Wolff ^a,d,h   Tannapfel, Andrea ^d  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c KLINIKEN MARIA HILF GMBH   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e PARACELSUS MEDICAL UNIVERSITY   (Austria)

^f KLINIKUM BREMEN OST   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Codon 13 mutation; Colorectal cancer; KRAS; Oxaliplatin; Prognosis

Indexed keywords

CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PLATINUM COMPLEX; RAS PROTEIN;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CODON; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; VERY ELDERLY; CANCER STAGING; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; MUTATION RATE; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CODON; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TREATMENT OUTCOME;

EID: 84864647242     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-349     Document Type: Article

References (24)

1. Bamford S, Dawson E, Forbes S, et al: The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004, 91(2):355-358.
2. Etienne-Grimaldi MC, Formento JL, Francoual M, et al: KRAS mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 2008, 14(15):4830-4835.
3. Andreyev HJ, Norman AR, Cunningham D, et al: RAS mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998, 90(9):675-684.
4. Maughan TS, Adams RA, Smith CG, et al: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377(9783):2103-2114.
5. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27(5):663-671.
6. Punt CJ, Tol J, Rodenburg CJ: Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2008, 26. May 20 suppl; abstr BA401.
7. Richman SD, Seymour MT, Chambers P, et al: KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial. JCO Dec 2009, 10:5931-5937.
8. Amado RG, Wolf M, Peeters M, et al: Wild type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
9. Lièvre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26(3):374-379.
10. Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360(14):1408-1417.
11. Tveit K, Guren T, Glimelius B, et al: Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab. as first-line treatment of metastatic colorectal cancer: The NORDIC VII Study (NCT00145314). 2010, ESMO:# LBA20.
12. De Roock W, Claes B, Bernascon D, et al: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2011, 12(6):594-603.
13. Tejpar S, Bokemeyer C, Celik I, et al: Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2011, 29. suppl; abstr 3511.
14. Porschen R, Arkenau HT, Kubicka S, et al: AIO Colorectal Study Group. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007, 25(27):4217-4223.
15. Bazan V, Migliavacca M, Zanna I, et al: Specific codon 13 KRAS mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 KRAS mutations are associated with mucinous histotype. Ann Oncol 2002, 13(9):1438-1446.
16. Zhang W, El-Khoueiry A, Yang D, et al: KRAS mutation status associated with clinical outcome in metastatic colorectal cancer patients treated with 5-fluorouracil/oxaliplatin. 2009, Gastrointestinal Cancers Symposium, abstr 340.
17. Moosmann N, Fischer von Weikersthal L, Vehling-Kaiser U, et al: Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With MetastaticColorectal Cancer: AIO KRK-0104-A Randomized Trial of the German AIO CRC Study Group. J Clin Oncol 2011, 29:1050-1058.
18. Ince WL, Jubb AM, Holden SN, et al: Association of KRAS, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005, 97(13):981-989.
19. Ocvirk J, Brodowicz T, Wrba F, et al: Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010, 16(25):3133-3143.
20. Reinacher-Schick A, Arnold D, Kubicka S, et al: Impact of KRAS status on survival in patients (pts.) with metastatic colorectal cancer (MCRC) undergoing Bevacizumab (BEV) containing chemotherapy regimen -Analysis of the AIO Colorectal Cancer Study Group. Ann Oncol 2010, 21(8). abstr 584PD.
21. Stinchcombe TE, Der CJ: Are all KRAS mutations created equal? Lancet Oncol 2011, 12(8):717-718.
22. Arkenau HT, Arnold D, Cassidy J, et al: Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008, 26(36):5910-5917.
23. Lenz HJ, Zhang W, Shi MM, et al: ERCC-1 gene expression levels and outcome to FOLFOX chemotherapy in patients enrolled in CONFIRM1 and CONFIRM2. J Clin Oncol 2008, 26. May 20 suppl; abstr 4131.
24. Friboulet L, Barrios-Gonzales D, Commo F, et al: Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. Clin Cancer Res 2011, 17(17):5562-5572.